DMK Pharmaceuticals regains full rights from US WorldMeds for Symjepi (epinephrine) injection and provides corporate update - Medthority
DMK Pharmaceuticals Corporation announced that it is reacquiring the rights to its Symjepi (epinephrine) Injection 0.3mg and Symjepi (epinephrine) Injection 0.15mg products from USWM, LLC
US World Meds previously held exclusive distribution and commercialization rights for Symjepi and Zimhi (naloxone) products in the United States, and was responsible for marketing, promotion and distribution efforts.
The Company is now actively seeking out-license opportunities for Symjepi in the US and globally, in addition to exploring other options with a focus on maximizing value for shareholders.
“Given our renewed focus on our core business, we are taking decisive actions that we believe will remove obstacles and improve our ability to drive long-term growth,” said Eboo Versi, M.D., Ph.D., CEO of DMK Pharmaceuticals. “This represents an important step in DMK’s ongoing transformation journey as we continue to execute against our operating plan and review our existing business relationships to ensure maximal benefit to DMK’s stakeholders and patients.”
Learning Zones
The Learning Zones are an educational resource for healthcare professionals that provide medical information on the epidemiology, pathophysiology and burden of disease, as well as diagnostic techniques and treatment regimens.
1 mins